Bayer and AstraZeneca gain early access to AI-driven "digital twins" through Altis collaboration

　　Canadian computational imaging company Altis Labs will lead an international project including pharmaceutical giants AstraZeneca and Bayer to promote The application of “digital twins” in clinical trials.

　　Digital twins can use simulation technology to help drug developers and clinicians understand how patients and/or therapies will perform under real-world conditions. In an Aug. 23 press release, Altis explained that the company, which develops artificial intelligence-powered computational imaging technology to accelerate clinical trials, will use the Nota imaging platform, which leverages prognostic artificial intelligence models to manage and analyze previous and Imaging data from current clinical trials.

　　Other members of the digital twin project include Canadian healthcare system Trillium Health Partners and the University of Calgary. SapienSecure The company will provide natural language processing tools.

　　Altis CEO Felix Baldauf-Lenschen "We have built and operated the world's largest real-world cancer imaging database for AI research in partnership with Canada's top cancer centers and leading biopharmaceutical sponsors, and we are excited to leverage our cutting-edge AI," said the release. Tools help improve patient outcomes."

　　In addition to participating in the program, AstraZeneca and Bayer will have early access to artificial intelligence twin models generated by Altis' Nota platform in four of their clinical trials.

　　Toronto-based Altis received $6 million in seed funding in June, which the company said at the time would be used to expand the Nota platform.

References:

1. Bayer, AstraZeneca gain early access to AI-driven 'digital twins' courtesy of Altis collab. https://www.fiercebiotech.com/cro/altis-leads-push-digital-twins-use-trials-includes-astrazeneca-and-bayer